Hyperinflammation with COVID-19: The key to patient deterioration?

Area of Science:

• Immunology
• Infectious Diseases
• Critical Care Medicine

Background:

• COVID-19 (coronavirus disease 2019) can trigger cytokine storm and hyperinflammation syndromes.
• Haemophagocytic lymphohistiocytosis (HLH) is a severe, life-threatening condition characterized by excessive immune activation.
• The risk of cytokine storm in COVID-19 patients necessitates exploring effective treatment strategies.

Observation:

• A 17-year-old male presented with symptoms of COVID-19, including fever, cough, and sore throat.
• Clinical examination revealed cervical lymphadenopathy and splenomegaly.
• Laboratory tests showed pancytopenia, elevated ferritin, triglycerides, and d-dimer, with an H-Score indicating a high probability of HLH.

Findings:

• The patient received Anakinra, a selective IL-1 receptor antagonist, and intravenous immunoglobulin.
• Rapid clinical improvement was observed, with fever resolving within 24 hours.
• Biochemical markers and organomegaly normalized, and the patient was discharged within 11 days with no adverse events.

Implications:

• This case suggests that severe COVID-19 pneumonitis may have an immunological basis.
• Anakinra showed efficacy in managing HLH secondary to COVID-19, even in patients with risk factors for deterioration.
• Anakinra presents a potential therapeutic option for managing hyperinflammation in COVID-19 patients, warranting further investigation.